CA2999279A1 - Targeted expression of chloride channels and methods of use thereof - Google Patents

Targeted expression of chloride channels and methods of use thereof Download PDF

Info

Publication number
CA2999279A1
CA2999279A1 CA2999279A CA2999279A CA2999279A1 CA 2999279 A1 CA2999279 A1 CA 2999279A1 CA 2999279 A CA2999279 A CA 2999279A CA 2999279 A CA2999279 A CA 2999279A CA 2999279 A1 CA2999279 A1 CA 2999279A1
Authority
CA
Canada
Prior art keywords
vector
subunit
promoter
glyr
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2999279A
Other languages
English (en)
French (fr)
Inventor
Griffith Roger Thomas
Shawnalea Jimee FRAZIER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goleini Inc
Original Assignee
Goleini Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goleini Inc filed Critical Goleini Inc
Publication of CA2999279A1 publication Critical patent/CA2999279A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2999279A 2015-10-01 2016-09-28 Targeted expression of chloride channels and methods of use thereof Abandoned CA2999279A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562235914P 2015-10-01 2015-10-01
US201562235920P 2015-10-01 2015-10-01
US62/235,920 2015-10-01
US62/235,914 2015-10-01
US201662303907P 2016-03-04 2016-03-04
US62/303,907 2016-03-04
US201662378509P 2016-08-23 2016-08-23
US62/378,509 2016-08-23
PCT/US2016/054199 WO2017058926A1 (en) 2015-10-01 2016-09-28 Targeted expression of chloride channels and methods of use thereof

Publications (1)

Publication Number Publication Date
CA2999279A1 true CA2999279A1 (en) 2017-04-06

Family

ID=58427328

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2999279A Abandoned CA2999279A1 (en) 2015-10-01 2016-09-28 Targeted expression of chloride channels and methods of use thereof

Country Status (11)

Country Link
US (1) US11407812B2 (OSRAM)
EP (1) EP3355938B1 (OSRAM)
JP (1) JP7097070B2 (OSRAM)
KR (2) KR20250012721A (OSRAM)
CN (1) CN108289965A (OSRAM)
AU (1) AU2016332847B2 (OSRAM)
BR (1) BR112018006480A2 (OSRAM)
CA (1) CA2999279A1 (OSRAM)
HK (1) HK1252915A1 (OSRAM)
SG (1) SG10201912703PA (OSRAM)
WO (1) WO2017058926A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019378036B2 (en) 2018-11-14 2026-05-07 Flagship Pioneering Innovations V, Inc Compositions and methods for compartment-specific cargo delivery
CA3120082A1 (en) * 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
CN110679548B (zh) * 2019-10-24 2021-11-30 南方医科大学南方医院 一种自闭症小鼠模型的构建方法
CN114214396A (zh) * 2020-06-30 2022-03-22 宁波市康宁医院(宁波市精神疾病预防控制中心、宁波市微循环与莨菪类药研究所) Gabrd甲基化作为抗海洛因复吸靶点的应用
CN115480485B (zh) * 2022-09-14 2024-09-10 南开大学 一种基于数据驱动模型的软镜扭转运动安全控制方法
GB202401492D0 (en) 2024-02-05 2024-03-20 Ucl Business Ltd Chloride channels and uses thereof
CN119331917B (zh) * 2024-10-28 2025-10-17 北京爱思益普生物科技股份有限公司 能够表达GlyR α1/β型GlyR的细胞株及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644643A (en) * 1969-10-13 1972-02-22 Unimed Inc Method of reducing intraocular pressure using glycine
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5527703A (en) 1994-05-25 1996-06-18 Merck & Co., Inc. DNA encoding glutamate gated chloride channels
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
NZ522888A (en) 2000-06-20 2005-01-28 Bionomics Ltd Mutations in the gamma aminobutyric acid type A receptor subunit ( GABA A ) associated with epilepsy
CA2438386A1 (en) * 2001-02-16 2002-08-29 Bristol-Myers Squibb Company Polynucleotides encoding a novel glycine receptor alpha subunit expressed in the gastrointestinal tract, hgra4, and splice variant thereof
US20040058313A1 (en) 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
WO2007127428A2 (en) * 2006-04-28 2007-11-08 University Of Florida Research Foundation, Inc. Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery
EP2061891B1 (en) 2006-08-24 2012-04-11 Virovek, Inc. Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor
WO2008143875A1 (en) 2007-05-14 2008-11-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
EP2058401A1 (en) * 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
WO2009133191A1 (en) 2008-04-30 2009-11-05 Dublin City University Compositions and methods for expressing in-frame multimeric proteins
WO2010042799A2 (en) 2008-10-09 2010-04-15 Howard Hughes Medical Institute Novel chimeric ligand-gated ion channels and methods of use thereof
WO2011137210A2 (en) 2010-04-30 2011-11-03 The Regents Of The University Of California Modulating compliance of trabecular meshwork
TW201306825A (zh) 2011-05-11 2013-02-16 Kirax Corp 狀況治療之改良套裝
JP2015527889A (ja) 2012-07-25 2015-09-24 ザ ブロード インスティテュート， インコーポレイテッド 誘導可能なｄｎａ結合タンパク質およびゲノム撹乱ツール、ならびにそれらの適用
EP2692868A1 (en) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
US9624288B2 (en) 2012-12-10 2017-04-18 University of Pittsburgh—of the Commonwealth System of Higher Education Engineered receptors and their use
JP2017501834A (ja) 2014-01-08 2017-01-19 サーキット セラピューティクス， インコーポレイテッド 高眼圧症の治療管理のための方法
WO2015149033A1 (en) 2014-03-27 2015-10-01 Circuit Therapeutics, Inc. System and method for therapeutic management of cough
WO2016055437A1 (en) 2014-10-06 2016-04-14 Arthrogen B.V. Aav-based gene therapy
JP2018531926A (ja) 2015-09-17 2018-11-01 コーダ バイオセラピューティクス， インコーポレイテッド 神経学的障害を処置するための組成物および方法
GB2547179A (en) 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
AU2017254652B2 (en) 2016-04-21 2022-12-01 Virovek, Inc. AAV production in insect cells, methods and compositions therefor

Also Published As

Publication number Publication date
BR112018006480A2 (pt) 2018-10-09
EP3355938A1 (en) 2018-08-08
HK1252915A1 (zh) 2019-06-06
KR20250012721A (ko) 2025-01-24
AU2016332847A2 (en) 2023-08-03
EP3355938A4 (en) 2019-03-06
AU2016332847B2 (en) 2023-08-10
JP2018533976A (ja) 2018-11-22
EP3355938B1 (en) 2024-02-07
SG10201912703PA (en) 2020-02-27
CN108289965A (zh) 2018-07-17
JP7097070B2 (ja) 2022-07-07
US20190010210A1 (en) 2019-01-10
WO2017058926A1 (en) 2017-04-06
AU2016332847A1 (en) 2018-04-19
US11407812B2 (en) 2022-08-09
KR20180072713A (ko) 2018-06-29

Similar Documents

Publication Publication Date Title
AU2016332847B2 (en) Targeted expression of chloride channels and methods of use thereof
JP7057281B2 (ja) 眼疾患のための遺伝子療法
JP7097398B2 (ja) ミオシリン（ｍｙｏｃ）緑内障を処置するためのアデノ随伴ウイルスベクター
ES2871527T3 (es) Virión de virus adenoasociado para usar en el tratamiento de la epilepsia
JP6949867B2 (ja) 神経の過剰興奮を治療するための方法および組成物
JP2020527335A (ja) 眼疾患のための遺伝子療法
CN114381465B (zh) 优化的cyp4v2基因及其用途
US8871733B2 (en) Treating glaucoma, cardiovascular diseases, and renal diseases
WO2014093251A1 (en) Engineered receptors and their use
KR20190028389A (ko) 디스펄린병증의 치료를 위한 절단형 디스펄린
EP4695613A2 (en) Methods of modifying neurons in vivo to treat and/or prevent amyotrophic lateral sclerosis (als)
CN118660970A (zh) 表达tpk的重组病毒及其治疗阿尔茨海默病的用途
US20250276094A1 (en) Vectors expressing methionine sulfoxide reductase (msr)
JP2020533313A (ja) 神経障害性疼痛を処置するための方法および組成物
WO2022263845A1 (en) Ocular disorders
CA3069045C (en) Novel polynucleotides encoding a human fkrp protein
WO2025158013A1 (en) Fusion proteins comprising extracellular domains of ror1 and ror2 to inhibit ror2 signalling and activate cartilage development
WO2024178364A1 (en) Gene therapy for treatment of pain
EP4587055A1 (en) Self-complementary aav vectors carrying dominant negative rhoa and methods of use to treat ocular diseases
WO2021087445A1 (en) Targeting deltafosb (δfosb) for treatment of dyskinesia
HK40066183B (zh) 靶向akt通路的神经保护性基因疗法
HK40066183A (zh) 靶向akt通路的神经保护性基因疗法
HK1262485B (zh) 用於治疗神经元的过度兴奋的方法和组合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210922

FZDE Discontinued

Effective date: 20240501